Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Obese Participants With Pulmonary Hypertension and HFpEF
Study of HS235 in Obese Participants with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction
∙ Participants are eligible to be included in the study only if they meet at least all the following criteria:
• Male or female, ≥ 18 years of age.
• \[Sub-population A only - using a remote PAP sensor\]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF System) implanted in the course of standard of care at least 90 days before Screening.
• Hemodynamic evidence of PH with:
‣ mPAP ≥ 25 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization AND,
‣ dPAP ≥ 15 mm Hg, as measured in supine position by the averaged 7-day values (weekly average) 2 weeks and 1 week before Randomization.
• \[Sub-population B only - without a remote PAP sensor\]
• Hemodynamic evidence of PH based on the presence of all the following RHC parameters obtained during the Screening period, prior to randomization:
‣ PVR ≥ 240 dyn\*sec/cm5 or ≥ 3 WU, and
‣ mPAP \> 20 mmHg, and
‣ PAWP \> 15 mmHg but \< 30 mmHg, and
‣ dPAP ≥ 15 mmHg.
• Established diagnosis of HFpEF with left ventricular ejection fraction (LVEF) ≥ 45 % as measured by echocardiography during Screening and and no documented LVEF \< 45% during the 2 years preceding Screening..
• New York Heart Association (NYHA) class II or III heart failure symptoms.
• Stable diuretic regimen during the screening period.
• Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) \< 90 at screening.
• 6-minute walking distance (6MWD) ≥ 100 m at screening.
• Body mass index ≥ 30 to ≤ 50 kg/m2 and Body weight ≤140 kg.
⁃ Ability to adhere to study visit schedule and understand and comply with all protocol requirements.